{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:06:02Z","timestamp":1787616362538,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,21]]},"DOI":"10.7759\/cureus.47417","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T09:53:17Z","timestamp":1697881997000},"source":"Crossref","is-referenced-by-count":1,"title":["Favipiravir Protects Enterocytes From Cell Death After Inflammatory Storm"],"prefix":"10.7759","author":[{"given":"Ugur","family":"Ozgurbuz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"Kabadayi Ensarioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damla","family":"Akogullari Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafize Seda","family":"Vatansever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00284-023-03305-0","article-title":"Association between inflammatory bowel disease and viral infections","volume":"80","author":"Dehghani T","year":"2023","unstructured":"Dehghani T, Gholizadeh O, Daneshvar M, et al.. Association between inflammatory bowel disease and viral infections. Curr Microbiol. 2023, 80:195. 10.1007\/s00284-023-03305-0","journal-title":"Curr Microbiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.228","article-title":"Dramatic increase in incidence of ulcerative colitis and Crohn\u2019s disease (1988-2011): a population-based study of French adolescents","volume":"113","author":"Ghione S","year":"2018","unstructured":"Ghione S, Sarter H, Fumery M, et al.. Dramatic increase in incidence of ulcerative colitis and Crohn\u2019s disease (1988-2011): a population-based study of French adolescents. Am J Gastroenterol. 2018, 113:265-72. 10.1038\/ajg.2017.228","journal-title":"Am J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ilar\/ilv030","article-title":"The intestinal microbiota in inflammatory bowel disease","volume":"56","author":"Becker C","year":"2015","unstructured":"Becker C, Neurath MF, Wirtz S. The intestinal microbiota in inflammatory bowel disease. ILAR J. 2015, 56:192-204. 10.1093\/ilar\/ilv030","journal-title":"ILAR J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/path.4463","article-title":"The molecular pathology of noroviruses","volume":"235","author":"Karst SM","year":"2015","unstructured":"Karst SM, Zhu S, Goodfellow IG. The molecular pathology of noroviruses. J Pathol. 2015, 235:206-16. 10.1002\/path.4463","journal-title":"J Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-018-0068-6","article-title":"Chronic intestinal inflammation in mice expressing viral flip in epithelial cells","volume":"11","author":"Ruder B","year":"2018","unstructured":"Ruder B, Murtadak V, St\u00fcrzl M, et al.. Chronic intestinal inflammation in mice expressing viral flip in epithelial cells. Mucosal Immunol. 2018, 11:1621-9. 10.1038\/s41385-018-0068-6","journal-title":"Mucosal Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04747-8","article-title":"Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir\/ritonavir and interferon in moderately ill patients with COVID-: a structured summary of a study protocol for a randomized controlled trial","volume":"19","author":"Hassaniazad M","year":"2020","unstructured":"Hassaniazad M, Bazram A, Hassanipour S, et al.. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir\/ritonavir and interferon in moderately ill patients with COVID-: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020, 19:1-3. 10.1186\/s13063-020-04747-8","journal-title":"Trials"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00734-20","article-title":"Influenza virus infection impairs the gut\u2019s barrier properties and favors secondary enteric bacterial infection through reduced production of short-chain fatty acids","volume":"89","author":"Sencio V","year":"2021","unstructured":"Sencio V, Gallerand A, Gomes Machado M, et al.. Influenza virus infection impairs the gut\u2019s barrier properties and favors secondary enteric bacterial infection through reduced production of short-chain fatty acids. Infect Immun. 2021, 89:e0073420. 10.1128\/IAI.00734-20","journal-title":"Infect Immun"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i27.4276","article-title":"Viral infections in inflammatory bowel disease: tips and tricks for correct management","volume":"27","author":"Craviotto V","year":"2021","unstructured":"Craviotto V, Furfaro F, Loy L, et al.. Viral infections in inflammatory bowel disease: tips and tricks for correct management. World J Gastroenterol. 2021, 27:4276-97. 10.3748\/wjg.v27.i27.4276","journal-title":"World J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03270-2","article-title":"Safety profile of COVID-19 drugs in a real clinical setting","volume":"78","author":"Chiu MN","year":"2022","unstructured":"Chiu MN, Bhardwaj M, Sah SP. Safety profile of COVID-19 drugs in a real clinical setting. Eur J Clin Pharmacol. 2022, 78:733-53. 10.1007\/s00228-021-03270-2","journal-title":"Eur J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1691\/ph.2021.01005","article-title":"Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora","volume":"76","author":"Dai T","year":"2021","unstructured":"Dai T, Wang M, Wang P, Dai L, Dai R, Meng Q. Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora. Pharmazie. 2021, 76:195-201. 10.1691\/ph.2021.01005","journal-title":"Pharmazie"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2020.05.006","article-title":"Psychopharmacology of COVID-19","volume":"61","author":"Bilbul M","year":"2020","unstructured":"Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL. Psychopharmacology of COVID-19. Psychosomatics. 2020, 61:411-27. 10.1016\/j.psym.2020.05.006","journal-title":"Psychosomatics"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90551-6","article-title":"The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials","volume":"11","author":"Hassanipour S","year":"2021","unstructured":"Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021, 11:11022. 10.1038\/s41598-021-90551-6","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080736","article-title":"Antiviral therapeutic approaches for SARS-CoV-2 infection: a systematic review","volume":"14","author":"Gil Mart\u00ednez V","year":"2021","unstructured":"Gil Mart\u00ednez V, Avedillo Salas A, Santander Ballest\u00edn S. Antiviral therapeutic approaches for SARS-CoV-2 infection: a systematic review. Pharmaceuticals (Basel). 2021, 14:736. 10.3390\/ph14080736","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.38137\/vetfarmatoksbulten.769889","article-title":"COVID-19 farmakoterapisi","volume":"11","author":"Dikmen BY","year":"2020","unstructured":"Dikmen BY, Ya\u011f\u0131z Pat, Dilekoz E, et al.. COVID-19 farmakoterapisi. Veteriner Farmakoloji ve Toksikoloji Derne\u011fi B\u00fclteni. 2020, 11:80-114. 10.38137\/vetfarmatoksbulten.769889","journal-title":"Veteriner Farmakoloji ve Toksikoloji Derne\u011fi B\u00fclteni"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5334\/gh.814","article-title":"The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: a systematic review and meta-analysis","volume":"15","author":"Matsushita K","year":"2020","unstructured":"Matsushita K, Ding N, Kou M, et al.. The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: a systematic review and meta-analysis. Glob Heart. 2020, 15:64. 10.5334\/gh.814","journal-title":"Glob Heart"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042921-112837","article-title":"Cytokine storm syndrome","volume":"74","author":"Cron RQ","year":"2023","unstructured":"Cron RQ, Goyal G, Chatham WW. Cytokine storm syndrome. Annu Rev Med. 2023, 74:321-37. 10.1146\/annurev-med-042921-112837","journal-title":"Annu Rev Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01043-6","article-title":"Cell deaths: involvement in the pathogenesis and intervention therapy of COVID-19","volume":"7","author":"Li X","year":"2022","unstructured":"Li X, Zhang Z, Wang Z, Guti\u00e9rrez-Castrell\u00f3n P, Shi H. Cell deaths: involvement in the pathogenesis and intervention therapy of COVID-19. Signal Transduct Target Ther. 2022, 7:186. 10.1038\/s41392-022-01043-6","journal-title":"Signal Transduct Target Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2012.v6.2.70","article-title":"Analysis of cytotoxicity induced by proinflammatory cytokines in the human alveolar epithelial cell line A549","volume":"6","author":"Muroya M","year":"2012","unstructured":"Muroya M, Chang K, Uchida K, et al.. Analysis of cytotoxicity induced by proinflammatory cytokines in the human alveolar epithelial cell line A549. Bioscience trends. 2012, 6:70-80. 10.5582\/bst.2012.v6.2.70","journal-title":"Bioscience trends"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2006.0130","article-title":"Constitutive expression of IL-18 and IL-18R in differentiated IEC-6 cells: effect of TNF-alpha and IFN-gamma treatment","volume":"28","author":"Kolinska J","year":"2008","unstructured":"Kolinska J, Lisa V, Clark JA, et al.. Constitutive expression of IL-18 and IL-18R in differentiated IEC-6 cells: effect of TNF-alpha and IFN-gamma treatment. J Interferon Cytokine Res. 2008, 28:287-96. 10.1089\/jir.2006.0130","journal-title":"J Interferon Cytokine Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki R","year":"2021","unstructured":"Karki R, Sharma BR, Tuladhar S, et al.. Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021, 184:149-168.e17. 10.1016\/j.cell.2020.11.025","journal-title":"Cell"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2022.01.021","article-title":"Incidence and risk factors of adverse drug reactions in patients with coronavirus disease 2019: a pharmacovigilance experience utilizing an ADR trigger tool","volume":"30","author":"Alshehail B","year":"2022","unstructured":"Alshehail B, Al Jamea Z, Chacko R, Alotaibi F, Ismail N, Alshayban D. Incidence and risk factors of adverse drug reactions in patients with coronavirus disease 2019: a pharmacovigilance experience utilizing an ADR trigger tool. Saudi Pharm J. 2022, 30:407-13. 10.1016\/j.jsps.2022.01.021","journal-title":"Saudi Pharm J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4149\/av_2017_01_48","article-title":"T-705 (Favipiravir) suppresses tumor necrosis factor \u03b1 production in response to influenza virus infection: a beneficial feature of T-705 as an anti-influenza drug","volume":"61","author":"Tanaka T","year":"2017","unstructured":"Tanaka T, Kamiyama T, Daikoku T, Takahashi K, Nomura N, Kurokawa M, Shiraki K. T-705 (Favipiravir) suppresses tumor necrosis factor \u03b1 production in response to influenza virus infection: a beneficial feature of T-705 as an anti-influenza drug. Acta Virol. 2017, 61:48-55. 10.4149\/av_2017_01_48","journal-title":"Acta Virol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039730","article-title":"Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials","volume":"10","author":"Arab-Zozani M","year":"2020","unstructured":"Arab-Zozani M, Hassanipour S, Ghoddoosi-Nejad D. Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials. BMJ Open. 2020, 10:e039730. 10.1136\/bmjopen-2020-039730","journal-title":"BMJ Open"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.55","article-title":"Pulmonary-intestinal cross-talk in mucosal inflammatory disease","volume":"5","author":"Keely S","year":"2012","unstructured":"Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012, 5:7-18. 10.1038\/mi.2011.55","journal-title":"Mucosal Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03137-5","article-title":"Effect of favipiravir and an anti-inflammatory strategy for COVID-19","volume":"24","author":"Yamamura H","year":"2020","unstructured":"Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care. 2020, 24:413. 10.1186\/s13054-020-03137-5","journal-title":"Crit Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/197682-favipiravir-protects-enterocytes-from-cell-death-after-inflammatory-storm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:07Z","timestamp":1707508507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/197682-favipiravir-protects-enterocytes-from-cell-death-after-inflammatory-storm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,21]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.47417","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,21]]}}}